167 related articles for article (PubMed ID: 35111667)
1. Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review.
Zhu J; Tao J; Dai Z; Tan Y; Jiang L; Wang Q; Lang J
Front Oncol; 2021; 11():771546. PubMed ID: 35111667
[TBL] [Abstract][Full Text] [Related]
2. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
[TBL] [Abstract][Full Text] [Related]
3. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
4. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.
Zhu J; Yang Y; Tao J; Wang SL; Chen B; Dai JR; Hu C; Qi SN; Li YX
Leukemia; 2020 Oct; 34(10):2576-2591. PubMed ID: 32651542
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
Front Oncol; 2022; 12():835389. PubMed ID: 35463354
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.
Li Y; Liu H; Sun C; Yin X; Tong J; Zhang X; Wang X; Yuan X; Zhang Z; Lu G; Gu Y; Li Y; Huang T; Qiao Z; Chen Y
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):405-416. PubMed ID: 33964352
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
Zhou HY; Zheng SP; Li AL; Gao QL; Ou QY; Chen YJ; Wu ST; Lin DG; Liu SB; Huang LY; Li FS; Zhu HY; Qiao GB; Lanuti M; Yao HR; Yu YF
EClinicalMedicine; 2020 Jul; 24():100422. PubMed ID: 32637899
[TBL] [Abstract][Full Text] [Related]
8. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
Front Oncol; 2022; 12():810580. PubMed ID: 35155246
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
[TBL] [Abstract][Full Text] [Related]
10. Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis.
Bao Y; Ma Z; Yuan M; Wang Y; Men Y; Hui Z
Thorac Cancer; 2022 Sep; 13(17):2515-2523. PubMed ID: 35891585
[TBL] [Abstract][Full Text] [Related]
11. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
12. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
13. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
[TBL] [Abstract][Full Text] [Related]
14. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
[TBL] [Abstract][Full Text] [Related]
15. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
16. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades.
Nishikawa G; Banik P; Thawani R; Kardosh A; Wood SG; Nabavizadeh N; Chen EY
J Gastrointest Oncol; 2022 Jun; 13(3):1454-1466. PubMed ID: 35837173
[TBL] [Abstract][Full Text] [Related]
18. Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma.
Yang YX; Zheng YZ; Gao TT; Liu SL; Xi M; Liu MZ; Wang JY; Qi SN; Yang Y; Zhao L
Cancer Med; 2022 Oct; 11(20):3751-3760. PubMed ID: 35434962
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
[TBL] [Abstract][Full Text] [Related]
20. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
